LUNA +12.97% 24H - Terra Network Update Planned
- LUNA surged 12.97% in 24 hours to $0.0811, but remains down 79.77% year-to-date amid market challenges. - Binance paused LUNA deposits/withdrawals on Dec 8, 2025, for a Terra network upgrade to secure the network during protocol updates. - Adverum’s LUNA Phase 2 trial showed a 90% reduction in anti-VEGF injections for wet AMD, with sustained efficacy and safety over two years. - Analysts anticipate increased Terra on-chain activity post-upgrade, though broader crypto volatility persists, urging investors
LUNA Experiences Significant Price Jump Amidst Ongoing Uptrend
On December 5, 2025, LUNA recorded a notable 12.97% increase within a single day, climbing to $0.0811 and extending its recent positive momentum. Over the previous week, the cryptocurrency advanced by 16.2%, with its monthly performance reflecting similar growth. However, LUNA is still down 79.77% since the start of the year, highlighting persistent challenges in the broader crypto market.
Temporary Suspension of LUNA Transactions Due to Terra Network Upgrade
Binance has revealed plans to temporarily halt deposits and withdrawals of the LUNA (Terra) token on December 8, 2025, starting at 20:05 UTC+8. This pause is necessary to accommodate a scheduled network upgrade, which is expected to conclude around 21:05 UTC+8, coinciding with block height 18,660,000. The exchange emphasized that this measure is intended to safeguard the network and ensure a seamless protocol transition.
Traders are encouraged to stay updated by following Binance’s official announcements for the latest information and post-upgrade confirmations. This upgrade highlights the ongoing commitment to advancing the Terra ecosystem.
LUNA Biotech Study Demonstrates Promising Results for Wet AMD Treatment
In a separate development, Adverum Biotechnologies, Inc. shared two-year follow-up results from its LUNA Phase 2 trial, evaluating Ixo-vec in patients with wet age-related macular degeneration (AMD). The company reported that Ixo-vec achieved nearly a 90% reduction in the need for anti-VEGF injections throughout the study, while maintaining stable anatomical outcomes and visual acuity across both dosage groups. Importantly, no new inflammation was detected after week 30 in the higher dose group.
The Phase 3 ARTEMIS trial is on track to complete enrollment by December 5, 2025, and the therapy continues to exhibit a strong safety profile. These results mark a major milestone in the pursuit of long-lasting gene therapies for chronic eye diseases.
Experts Anticipate Ongoing Growth for the Terra Ecosystem
Market analysts believe that the Terra network’s latest upgrade could spur greater on-chain activity, supporting the project’s vision for sustained expansion. While recent price gains are largely attributed to the upgrade announcement and positive biotech news, overall market volatility persists. Investors are advised to consider both developments within the Terra ecosystem and broader economic trends impacting the cryptocurrency sector.
As the Terra network evolves and LUNA’s biotech initiatives progress, the intersection of blockchain technology and medical innovation may help attract renewed attention from investors.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
MicroStrategy Halts Bitcoin Buying Amid Market Strategies Shift
Russia Considers Bitcoin Mining as Official Export
WLFI Sees Hidden Bullish Divergence, Targets $0.18
PEPE Website Hacked; Users Redirected to Malware